BioAgeLabs aims to help those medications work better with a lead drug candidate envisioned as a part of new GLP-1 combination therapies. With a key clinical trial already underway, BioAge has ...
BioAgeLabs (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, visits the Nasdaq ...
Results that may be inaccessible to you are currently showing.